Exodus Point Capital Management, LP Aveo Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$6.61 - $8.72 $96,162 - $126,858	14,548 New	14,548 $120,000
Q2 2022 Aug 19, 2022	SELL	$3.51 - $6.67 $38,764 - $73,663	-11,044 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.15 - $6.01 $693 - $1,322	-220 Reduced 1.95%	11,044 $62,000
Q4 2021 Feb 11, 2022	BUY	$4.69 - $7.4 $52,828 - $83,353	11,264 New	11,264 $53,000
Q3 2021 Nov 15, 2021	SELL	$5.12 - $6.89 $384,076 - $516,853	-75,015 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.21 - $7.45 $341,196 - $409,325	54,943 Added 273.73%	75,015 $494,000
Q1 2021 May 17, 2021	BUY	$5.97 - $15.28 $119,829 - $306,700	20,072 New	20,072 $147,000
Q3 2020 Nov 16, 2020	SELL	$4.16 - $6.26 $157,763 - $237,404	-37,924 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.47 - $9.99 $131,596 - $378,860	37,924 New	37,924 $195,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.